We’re very excited to announce our new partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the University of Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale.
Under the partnership, more than 200 recombinant antibodies made by the Recombinant Antibody Network will be engineered into new formats and made available to a wider scientific audience via our online reagents catalog.
The recombinant antibodies are targeted against proteins involved in key research areas such as transcription regulation, chromatin biology and infectious disease control. Our team will engineer the antibodies into different species to readily enable co-labelling studies, as well as into antibody fragment formats to reduce background in immunoprecipitation studies. All the antibodies are defined at the amino acid level to ensure batch-to-batch reproducibility, high purity and low endotoxin levels.
Over the coming months, the recombinant antibodies will be added to our reagents catalog here.
“We’re excited to partner with the Recombinant Antibody Network, which has been visionary in its efforts to generate a comprehensive set of recombinant antibodies for biomedical research. The Network shares our mission to further the availability of recombinant antibodies to advance scientific research, and we’re eager to bring this valuable collection of antibodies to a wider audience in newly engineered formats.”
— Amelia Gibson, PhD, MBA, Absolute Antibody Director of Business Development
You can read the full press release here.
Antibody Engineering and Therapeutics – Booth #402
4-9th December 2022
San Diego, California